Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on immunotherapy that entered the public markets through a special purpose acquisition company transaction, with its de-SPAC process completing in late 2022. The company filed an 8-K current report with the SEC on December 29, 2022, disclosing a material event tied to that business combination. Operating in the healthcare and biotechnology sector, Estrella is developing novel immunotherapeutic candidates targeting oncology and autoimmune conditions. The December 2022 filing marks the company's transition from blank-check vehicle to operating public entity. Sign up at SpacDesk for full filing history, sponsor data, and deal analytics on ESLA and the broader SPAC universe.